The safety and efficacy of the SYNERGY Stent has not been established in CTOs
* Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific’s involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products.
The EVOLVE II Clinical Trial studied 1,684 patients, the broadest and most complex patient population ever studied in a U.S. pivotal stent trial. The results showed exceptionally low stent thrombosis favoring BP-DES versus PP-DES at 4-Years.1
† CEC confirmed MI/TLR/ST Day 901 in the SYNERGY arm 37 y/o male patient had 1,1,0 distal RCA/PDA bifurcation lesion, and a second lesion in the mid-LAD treated during the index procedure (patient was discharged on DAPT [clopidogrel]. On day 840, patient had TLR of 75% in-stent restenosis of the distal RCA/PDA lesion performed with drug coated balloon (patient was discharged on DAPT [prasugrel]). On day 901, patient developed severe chest pain, ST elevation and marked elevation of cardiac enzymes. Found to have ST of RCA/PDA lesion, which was successfully treated with another stent. ITT; Patients who did not receive a study stent were censored at 1 year; KM Event Rate; log-rank P values.
P-value from the one-sided Clopper-Pearson test is <0.025, the 12-month TLF rate from SYNERGY is concluded to be less than the performance goal (14.5%)
One-sided 97.5% Clopper Pearon Upper Confidence Bound (UCB) Target lesion failure (TLF) defined as: Cardiac death, or MI related to the target vessel (based on CK-MB >3x URL), or Ischemia-driven target lesion revascularization
The EVOLVE first human use trial demonstrated outstanding long-term safety and performance with the SYNERGY BP Stent.
EVOLVE Trial 5-Year Results3